{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=49", "query": { "intervention": "Placebo- matched", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 7061, "total_pages": 707, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=50&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=48&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T17:21:04.744Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06220604", "title": "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "JNJ-77242113", "type": "DRUG" }, { "name": "JNJ-77242113 Matching Placebo", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Deucravacitinib Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 731, "start_date": "2024-03-09", "completion_date": "2027-09-20", "has_results": true, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Encinitas, California • Encino, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06220604" }, { "nct_id": "NCT06163326", "title": "A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vitiligo" ], "interventions": [ { "name": "Ritlecitinib", "type": "DRUG" }, { "name": "Ritlecitinib 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 394, "start_date": "2024-01-19", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 22, "location_summary": "Encinitas, California • Huntington Beach, California • Los Angeles, California + 16 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06163326" }, { "nct_id": "NCT06899178", "title": "Atomoxetine in Melanocortin Obesity Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanocortin Obesity Syndrome", "MCOS" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-01", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 3, "location_summary": "New York, New York • Columbus, Ohio • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06899178" }, { "nct_id": "NCT01490450", "title": "Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "Placebo matching BMS-945429", "type": "BIOLOGICAL" }, { "name": "BMS-945429", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2011-12", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 8, "location_summary": "San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490450" }, { "nct_id": "NCT01186991", "title": "Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Onartuzumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab Placebo", "type": "DRUG" }, { "name": "Onartuzumab Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 185, "start_date": "2011-03", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 23, "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186991" }, { "nct_id": "NCT04655118", "title": "Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Indolent Systemic Mastocytosis" ], "interventions": [ { "name": "TL-895", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telios Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2020-10-22", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 6, "location_summary": "Aurora, Colorado • Rochester, Minnesota • Canton, Ohio + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04655118" }, { "nct_id": "NCT01350804", "title": "Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "AIN457", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 551, "start_date": "2011-09", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 44, "location_summary": "Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Freemont", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01350804" }, { "nct_id": "NCT07787585", "title": "Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypothyroidism" ], "interventions": [ { "name": "Levothyroxine Pill", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spyridoula Maraka", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 138, "start_date": "2027-10", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 3, "location_summary": "Little Rock, Arkansas • Gainesville, Florida • Rochester, Minnesota", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07787585" }, { "nct_id": "NCT05668091", "title": "A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID" ], "interventions": [ { "name": "Nirmatrelvir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harlan M Krumholz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-04-14", "completion_date": "2024-08-21", "has_results": false, "last_update_posted_date": "2024-12-02", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05668091" }, { "nct_id": "NCT02720263", "title": "A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ASP4345", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 48, "start_date": "2016-03-28", "completion_date": "2017-06-08", "has_results": false, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-11-12T17:21:04.744Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02720263" } ] }